Drug-induced prevention of gastrectomy- and ovariectomy-induced osteopaenia in the young female rat.
Artikel i vetenskaplig tidskrift, 2002

Both ovariectomy (Ovx) and gastrectomy (Gx) induce osteopaenia in rats and humans. While the effect of Ovx has been ascribed to oestrogen deficiency, the underlying mechanism behind Gx is poorly understood. Alendronate, oestrogen and parathyroid hormone (PTH) are known to prevent the osteopaenia induced by Ovx in rats. The purpose of the present study was to determine whether alendronate, oestrogen or PTH could also prevent Gx-evoked osteopaenia. Rats were Ovx-, Gx-, or were sham-operated (Sham) and were then treated with alendronate (50 micro g/kg/day), oestrogen (10 micro g/kg/day) or PTH(1-84) (75 micro g/kg/day) for eight weeks. At sacrifice, serum PTH was unaffected by surgery (Ovx, 64+/-8 pg/ml; Gx, 75+/-13 pg/ml; Sham, 58+/-11 pg/ml). The bone mineral density (BMD) of the fifth lumbar vertebra (L5) was analysed. Ovx and Gx reduced the BMD (ash weight/Volume) of the L5 by 15+/-4% and 22+/-3% respectively. Trabecular BMD and the cortical bone mineral content (BMC) of the femur were assessed using peripheral computed tomography. Both Ovx and Gx markedly reduced trabecular BMD in the metaphyseal area of the distal femur (Ovx, -37+/-7%; Gx, -49+/-7%). The cortical BMC of the femur was only slightly reduced. Alendronate prevented trabecular bone loss after both Ovx and Gx, while oestrogen and PTH prevented trabecular bone loss after Ovx but not after Gx. In conclusion, the bisphosphonate alendronate prevented both Ovx- and Gx-induced trabecular bone loss. In contrast, PTH and oestrogen prevented Ovx-induced but not Gx-induced trabecular bone loss, suggesting that the mechanism behind the trabecular bone loss in Ovx rats differs from that in Gx rats. The results support the notion that the mechanism of action for the bone-sparing effect of these drugs differs. The ability of alendronate, and probably also other bisphosphonates, to prevent Gx-evoked osteopaenia in the rat might be of potential clinical interest when dealing with post-Gx osteopaenia in humans.

Humans

blood

prevention & control

Rats

blood

Metabolic

therapeutic use

Analysis of Variance

Postmenopausal

Rats

Tomography

therapeutic use

Animal

Osteoporosis

Models

blood

Animals

Gastrectomy

Bone Diseases

Recombinant Proteins

X-Ray Computed

Osteocalcin

Biological Markers

Parathyroid Hormone

Random Allocation

Bone Density

Sprague-Dawley

Female

Alendronate

blood

Ovariectomy

drug effects

Estradiol

Gastrins

therapeutic use

therapeutic use

Författare

Niklas Andersson

Göteborgs universitet

V V Surve

Daisy Lehto-Axtelius

Claes Ohlsson

Göteborgs universitet

Rolf Håkanson

K Andersson

Birgitta Ryberg

Journal of Endocrinology

0022-0795 (ISSN)

Vol. 175 3 695-703

Ämneskategorier

MEDICIN OCH HÄLSOVETENSKAP

PubMed

12475380

Mer information

Skapat

2017-10-10